CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial

Trial Profile

CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Lapatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CONKO-008
  • Most Recent Events

    • 29 Jun 2013 Planned number of patients changed from 18 to 95 as reported by European Clinical Trials Database.
    • 29 Jun 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-009928-37).
    • 26 Aug 2011 New source identified and integrated (German Clinical Trials Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top